modelFusidicAcid
Extends from Pharmacolibrary.Drugs.ATC.D.D09AA02.
Information
| name: | FusidicAcid | |
| ATC code: | D09AA02 | route: | oral |
| compartments: | 2 | |
| dosage: | 500 | mg |
| volume of distribution: | 12.5 | L |
| clearance: | 0.36 | L/h |
| other parameters in model implementation | ||
Fusidic acid is a steroidal antibiotic, primarily used for the treatment of infections caused by Staphylococcus species, including methicillin-resistant Staphylococcus aureus (MRSA). It is used both topically and systemically. Its main application is in skin infections, conjunctivitis, and occasionally for more severe systemic staphylococcal infections in combination with other antibacterials. Fusidic acid is approved and in use today in many countries, though its use for systemic infections is more restricted.
Pharmacokinetics
Pharmacokinetic parameters after a single 500 mg oral dose in healthy adult volunteers.
References
Bulitta, JB, et al., & Ambrose, PG (2013). Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance. Antimicrobial agents and chemotherapy 57(1) 498–507. DOI:10.1128/AAC.01354-12 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23147726
Marsot, A, et al., & Blin, O (2017). Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid. British journal of clinical pharmacology 83(5) 1039–1047. DOI:10.1111/bcp.13178 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27813241
Marsot, A, et al., & Guilhaumou, R (2020). Evaluation of current dosing guidance for oral rifampicin treatment in adult patients with osteoarticular infections. British journal of clinical pharmacology 86(11) 2319–2324. DOI:10.1111/bcp.14319 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32330996
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
| Pharmacolibrary.Types.TransferRate | ka (from PK_2C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_2C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)